Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990145 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT00990145 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT00990145, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This was a Phase I, single-center, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of orally administered EDP-322 in healthy adult volunteers.
Interventions
- DRUG EDP-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00990145
The ClinicalTrials.gov registry entry for NCT00990145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EDP-322 is the first listed.
NCT00990145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00990145 about?
NCT00990145 is a clinical study titled "Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers". This was a Phase I, single-center, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of orally administered EDP-322 in healthy adult volunteers.
What is the current status of trial NCT00990145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2008-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00990145?
The interventions under investigation include: EDP-322 (DRUG).
Who is sponsoring clinical trial NCT00990145?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.